By Frank Prenesti
Date: Wednesday 07 Jan 2026
(Sharecast News) - GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 patients from 29 countries.
| Japan approves GSK treatment for severe asthma | 06-Jan-2026 | ShareCast |
| GSK's COPD treatment approved by Chinese regulat... | 05-Jan-2026 | ShareCast |
| Director/PDMR Shareholding | 22-Dec-2025 | ShareCast |
| GSK to lower drug prices and expand access in US | 22-Dec-2025 | ShareCast |
| Transaction in Own Shares | 22-Dec-2025 | ShareCast |
| EC approval of Shingrix PFS | 07-Jan-2026 | 07:05 | RNS |
| Positive phase 3 data for GSK's bepirovirsen | 07-Jan-2026 | 07:00 | RNS |
| Exdensur approved in Japan | 06-Jan-2026 | 07:00 | RNS |
| Director/PDMR Shareholding | 05-Jan-2026 | 15:30 | RNS |
| Total Voting Rights | 05-Jan-2026 | 15:00 | RNS |
| GSK’s hepatitis B drug shows promise in trials | 07-Jan-2026 | Times |
| GlaxoSmithKline scraps sale of old drugs | 05-Dec-2014 | Telegraph |
| Glaxo sharpens axe to save £1bn as insurers and ... | 01-Dec-2014 | The Independent |
| GSK to cut hundreds of US jobs | 01-Dec-2014 | Telegraph |
| Ebola vaccine trials 'encouraging', says GSK | 27-Nov-2014 | Telegraph |
| Questor :GlaxoSmithKline | 16-Apr-2014 | Telegraph |
| Questor:GlaxoSmithKline | 06-Oct-2011 | Telegraph |
| Questor:GlaxoSmithKline | 11-Aug-2011 | Telegraph |
| Questor tip: GlaxoSmithKline | 28-Jul-2011 | Telegraph |
| Investment Column: GlaxoSmithKline | 27-Jul-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 1,872.00p |
| Change Today | -27.50p |
| % Change | -1.45 % |
| 52 Week High | 1,909.73 |
| 52 Week Low | 1,264.00 |
| Volume | 2,053,430 |
| Shares Issued | 4,075.43m |
| Market Cap | £76,292m |
| Beta | 0.98 |
| RiskGrade | 129 |
| Value | ![]() |
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Strong Buy | 4 |
| Buy | 3 |
| Neutral | 14 |
| Sell | 2 |
| Strong Sell | 0 |
| Total | 23 |

| Latest | Previous | |
|---|---|---|
| Q3 | Q2 | |
| Ex-Div | 13-Nov-25 | 14-Aug-25 |
| Paid | 08-Jan-26 | 09-Oct-25 |
| Amount | 16.00p | 16.00p |
| Time | Volume / Share Price |
| 12:17 | 60 @ 1,872.00p |
| 12:17 | 5 @ 1,872.00p |
| 12:17 | 1 @ 1,872.50p |
| 12:17 | 234 @ 1,871.50p |
| 12:17 | 774 @ 1,871.50p |
You are here: research